Competitive Problems in the Drug Industry : Drug Testing.
Report, prepared by Janet E. Lemke (CRS) in anticipation of 96th Congress consideration of S. 1075, the Drug Regulation Reform Act of 1979, reviewing problems with the FDA system of drug testing and evaluation raised during 1968-69 hearings before the Subcom on Monopoly. Contains update of drug test...
| Corporate Authors: | , |
|---|---|
| Format: | Government Document eBook |
| Language: | English |
| Published: |
[Place of publication not identified] :
[publisher not identified],
1979-1980.
|
| Series: | U.S. Congressional Research.
|
| Subjects: | |
| Online Access: | Connect to the full text of this electronic book |
| Summary: | Report, prepared by Janet E. Lemke (CRS) in anticipation of 96th Congress consideration of S. 1075, the Drug Regulation Reform Act of 1979, reviewing problems with the FDA system of drug testing and evaluation raised during 1968-69 hearings before the Subcom on Monopoly. Contains update of drug testing issues, including difficulty in selecting an independent investigator to conduct drug tests, substandard quality of drug tests, use of humans in drug tests, and delays in FDA approval of new drugs. Appendices (p. 115-142) include bibliography (p. 115-118) and "General Considerations for the Clinical Evaluation of Drugs," FDA, Sept. 1977 (p. 129-142). |
|---|---|
| Item Description: | Record is based on bibliographic data in ProQuest U.S. Congressional Research Digital Collection (last viewed June 2010). Reuse except for individual research requires license from ProQuest, LLC. CRS Report. Electronic resource. |
| Physical Description: | 1 online resource. |